Knowing What's Out There: Awareness of Non-Alcoholic Fatty Liver Disease

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2015 Mar 24

PMID 25798442

Citations 20

Authors

Vishal Ghevariya

Nan Sandar

Kishor Patel

Nehal Ghevariya

Ruchit Shah

Joshua Aron

Sury Anand

Affiliations

Soon will be listed here.

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder, which poses a significant health burden in the western countries. As the epidemic of obesity slides health downward, the incidence of NAFLD is evidently increasing.

Aim: We aimed to ascertain the awareness of NAFLD and its risk factors in the general population, which may be helpful in designing educational tools to promote prevention, early detection, and treatment of this disorder.

Methods: A survey of 5000 non-institutionalized residents of Brooklyn, NY, USA was conducted. Sixteen items were included in the survey questionnaire including awareness of fatty liver, predisposing factors of NAFLD, awareness of cirrhosis, and conditions that advance to cirrhosis. The questionnaire also addressed awareness of prevention, diagnostic methods and treatment of NAFLD, and education of physicians to their patients about NAFLD.

Results: Overwhelming majority of the subjects was not aware of NAFLD and stated that their physicians did not have a discussion about NAFLD.

Conclusion: Non-alcoholic fatty liver disease is a preventable liver disorder with limited treatment options. Thorough counseling by primary care physicians can be of paramount importance in preventive strategy for NAFLD. We should target our teenage population in an era of obesity epidemics of all times.

Citing Articles

Submicron Dispersions of Phytosterols Reverse Liver Steatosis with Higher Efficacy than Phytosterol Esters in a Diet Induced-Fatty Liver Murine Model.

Gillet R, Cerda-Drago T, Branes M, Valenzuela R Int J Mol Sci. 2025; 26(2).

PMID: 39859279 PMC: 11766071. DOI: 10.3390/ijms26020564.

Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy.

Leith D, Lin Y, Brennan P touchREV Endocrinol. 2024; 20(2):5-9.

PMID: 39526052 PMC: 11548366. DOI: 10.17925/EE.2024.20.2.2.

Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations.

Danpanichkul P, Suparan K, Prasitsumrit V, Ahmed A, Wijarnpreecha K, Kim D Clin Mol Hepatol. 2024; 31(1):74-89.

PMID: 39439408 PMC: 11791619. DOI: 10.3350/cmh.2024.0631.

Knowledge, Attitudes, and Determinants of Nonalcoholic Fatty Liver Disease Among Adults in Jazan Province: A Cross-Sectional Study.

Someili A, Mohrag M, Rajab B, Daghreeri A, Hakami F, Jahlan R Cureus. 2024; 16(8):e66837.

PMID: 39280536 PMC: 11398846. DOI: 10.7759/cureus.66837.

Non-alcoholic fatty liver disease related knowledge among a sample of Egyptians: an exploratory cross-sectional study.

Hegazy M, Elshafei A, Salem M, Ashoush O, Abdelghani A Front Public Health. 2024; 11:1290842.

PMID: 38872989 PMC: 11173582. DOI: 10.3389/fpubh.2023.1290842.

References

Tsai C, Li T, Lin C . Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease. South Med J. 2008; 101(9):900-5. DOI: 10.1097/SMJ.0b013e31817e8af9. View

Bouzianas D, Bouziana S, Hatzitolios A . Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids. Nutr Rev. 2013; 71(11):753-71. DOI: 10.1111/nure.12073. View

Lazo M, Hernaez R, Eberhardt M, Bonekamp S, Kamel I, Guallar E . Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013; 178(1):38-45. PMC: 3698993. DOI: 10.1093/aje/kws448. View

Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M . Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med. 1988; 27(2):142-9. DOI: 10.2169/internalmedicine1962.27.142. View

Bellentani S, Saccoccio G, Masutti F, Croce L, Brandi G, Sasso F . Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000; 132(2):112-7. DOI: 10.7326/0003-4819-132-2-200001180-00004. View

Harris M, Flegal K, Cowie C, Eberhardt M, Goldstein D, LITTLE R . Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998; 21(4):518-24. DOI: 10.2337/diacare.21.4.518. View

Mofrad P, Contos M, Haque M, Sargeant C, Fisher R, Luketic V . Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003; 37(6):1286-92. DOI: 10.1053/jhep.2003.50229. View

Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezynska-Kurtycz J, Milkiewicz P . [Non-alcoholic fatty liver disease--new view]. Pol Merkur Lekarski. 2008; 24(144):568-71. View

. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(5):1702-4. DOI: 10.1053/gast.2002.36569. View

10.

Wadden T, Berkowitz R, Womble L, Sarwer D, Phelan S, Cato R . Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005; 353(20):2111-20. DOI: 10.1056/NEJMoa050156. View

11.

Silverman J, OBrien K, Long S, Leggett N, Khazanie P, Pories W . Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 1990; 85(10):1349-55. View

12.

Flegal K, CARROLL M, Kuczmarski R, Johnson C . Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998; 22(1):39-47. DOI: 10.1038/sj.ijo.0800541. View

13.

Creutzfeldt W, Frerichs H, SICKINGER K . Liver diseases and diabetes mellitus. Prog Liver Dis. 1970; 3:371-407. View

14.

Ioannou G, Weiss N, Boyko E, Mozaffarian D, Lee S . Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology. 2006; 43(5):1145-51. DOI: 10.1002/hep.21171. View

15.

Luyckx F, Desaive C, Thiry A, Dewe W, Scheen A, Gielen J . Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998; 22(3):222-6. DOI: 10.1038/sj.ijo.0800571. View

16.

Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci M, Saviano M . Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci. 1997; 42(7):1428-32. DOI: 10.1023/a:1018850223495. View

17.

Said A, Gagovic V, Malecki K, Givens M, Nieto F . Primary care practitioners survey of non-alcoholic fatty liver disease. Ann Hepatol. 2013; 12(5):758-65. View

18.

Sookoian S, Pirola C . Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008; 49(4):600-7. DOI: 10.1016/j.jhep.2008.06.012. View

19.

Dunn W, Xu R, Wingard D, Rogers C, Angulo P, Younossi Z . Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008; 103(9):2263-71. PMC: 2574666. DOI: 10.1111/j.1572-0241.2008.02034.x. View

20.

Lazo M, Hernaez R, Bonekamp S, Kamel I, Brancati F, Guallar E . Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011; 343:d6891. PMC: 3220620. DOI: 10.1136/bmj.d6891. View